Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000205319 | SCV000260200 | pathogenic | Fanconi anemia complementation group O | 2016-07-09 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exon 8 of the RAD51C gene. This deletion is expected to create a premature translational stop signal in the last exon. While this is not anticipated to result in nonsense mediated decay, it is expected to create a truncated RAD51C protein. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a RAD51C-related disease. This variant is expected to cause the loss or disruption of 55 C-terminal amino acid residues from the RAD51C protein. While the effect of this particular sequence change on RAD51C function has not been tested, the C-terminal region of RAD51C is known to contain a nuclear localization signal, and the deletion of 11 C-terminal residues leads to cellular mislocalization of the protein, as well as reduced MMC resistance compared to the wild-type protein (PMID: 12966089). For these reasons, this variant has been classified as Pathogenic. |